Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:00:38.088Z.
Calculation as of: 2026-10-06T12:00:38.088Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$114.24M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.77M
EV/Sales Ratio
N/A
TTM Avg
52.04x
3Y Avg
28.07x
5Y Avg
28.07x
Market Cap
$116.59M
EV/Sales Ratio
13727.64x
TTM Avg
11863.26x
3Y Avg
8138.14x
5Y Avg
6150.74x
Market Cap
$111.17M
EV/Sales Ratio
N/A
TTM Avg
1.96x
3Y Avg
1.96x
5Y Avg
1.96x
Market Cap
$117.43M
EV/Sales Ratio
2.52x
TTM Avg
9.70x
3Y Avg
9.36x
5Y Avg
78.10x
Market Cap
$118.02M
EV/Sales Ratio
11.81x
TTM Avg
18.19x
3Y Avg
13.45x
5Y Avg
23.44x
Market Cap
$109.49M
EV/Sales Ratio
2.08x
TTM Avg
3.15x
3Y Avg
1.92x
5Y Avg
2.95x
Market Cap
$108.39M
EV/Sales Ratio
N/A
TTM Avg
86.52x
3Y Avg
45.27x
5Y Avg
201.32x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $114.24M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | 52.04x | 28.07x | 28.07x |
| Genelux Corporation (GNLX)vs › | $116.59M | 13727.64x | 11863.26x | 8138.14x | 6150.74x |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 1.96x | 1.96x | 1.96x |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | 2.52x | 9.70x | 9.36x | 78.10x |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 11.81x | 18.19x | 13.45x | 23.44x |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 2.08x | 3.15x | 1.92x | 2.95x |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | N/A | 86.52x | 45.27x | 201.32x |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | 3.42x | 1.78x | 1.24x | 1.09x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
